Article Text

Download PDFPDF
P1239 Better quality of life in BRCA mutation carriers after salpingectomy with delayed oophorectomy compared to salpingo-oophorectomy; first results of the Dutch TUBA study
  1. MP Steenbeek1,
  2. MG Harmsen1,
  3. N Hoogerbrugge2,
  4. M Arts-de Jong1,
  5. AHEM Maas3,
  6. JB Prins4,
  7. J Bulten5,
  8. S Teerenstra6,
  9. JMJ Piek7,
  10. HC van Doorn8,
  11. M van Beurden9,
  12. MJE Mourits10,
  13. RP Zweemer11,
  14. KN Gaarenstroom12,
  15. BFM Slangen13,
  16. MC Vos14,
  17. LRCW van Lonkhuijzen15,
  18. NM van Mello16,
  19. MJ Apperloo17,
  20. SFPJ Coppus18,
  21. LFAG Massuger1,
  22. RPMG Hermens19 and
  23. JA de Hullu1
  1. 1Obstetrics and Gynaecology
  2. 2Human Genetics
  3. 3Cardiology
  4. 4Medical Psychology
  5. 5Pathology
  6. 6Department for Health Evidence, Radboud University Medical Center, Nijmegen
  7. 7Catharina Hospital, Eindhoven
  8. 8Erasmus MC Cancer Clinic, Rotterdam
  9. 9Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam
  10. 10Gynaecologic Oncology, University Medical Center Groningen, Groningen
  11. 11UMC Utrecht Cancer Centre, Utrecht
  12. 12Leiden University Medical Centre, Leiden
  13. 13Maastricht University Medical Centre, Maastricht
  14. 14Elisabeth-TweeSteden Hospital, Tilburg
  15. 15Amsterdam UMC, Location AMC
  16. 16Amsterdam UMC, Location VUmc, Amsterdam
  17. 17Medical Center Leeuwarden, Leeuwarden
  18. 18Maxima Medical Center, Veldhoven
  19. 19Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands


Introduction/Background Risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 is recommended for BRCA1/2 germline mutation carriers. As recent data indicate the Fallopian tube as origin of high grade serous ovarian carcinoma (HGSC), risk-reducing salpingectomy (RRS) with delayed oophorectomy (RRO) is studied as an innovative strategy to delay premature menopause. The TUBA-study (NCT02321228) compares menopause-related quality of life (QOL) between standard RRSO and the innovative RRS with delayed RRO.

Methodology A multicentre preference trial in 13 Dutch centres started in January 2015. BRCA1/2 mutation carriers choose between the standard strategy (RRSO at age 35–40 (BRCA1) or 40–45 (BRCA2)) and the innovative strategy (RRS with delayed RRO until the age of 40–45 (BRCA1) or 45–50 years (BRCA2)).

Results August first 2019, 493 participants were included with a mean age of 37 years: 51% carried a BRCA1 and 49% carried a BRCA2 mutation. In total, 72% of women chose RRS with delayed RRO. At three months and one year after surgery, data showed a better menopause-related QOL in women after RRS when compared to women after RRSO (P<0.001), also after adjustment for age, hospital and baseline score. Additionally, a decline in cancer worry was found at three months and one year after surgery in both groups.

Conclusion The menopause-related QOL is significantly better in BRCA mutation carriers after RRS (with delayed RRO) when compared to RRSO. Furthermore, a favourable effect on cancer worry is found among participating women in both arms. At the time of the conference we will have finished recruitment and have one year of follow up in more than 300 women. Based on our results, the Dutch TUBA and American WISP study (NCT02760849) are initializing a combined international TUBA-WISP-II study to assess the safety of RRS with delayed RRO in BRCA germline mutation carriers.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.